A Phase III Study of Bevacizumab and Paclitaxel in Combination With Atezolizumab as a Treatment for Locally Advanced Unresectable or Metastatic Hormone Receptor-positive HER2 Negative Breast Cancer

NCT04732598 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

281

Enrollment

OTHER

Sponsor class

Conditions

Breast Cancer

Interventions

DRUG: Paclitaxel + bevacizumab therapy
DRUG: Paclitaxel + bevacizumab + atezolizumab

Sponsor

Japanese Foundation for Cancer Research

Collaborators

[object Object]